ArticleClinical, cosmetic and investigational dermatology2025
Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erosive pustular dermatosis of the lower legs (EPDL): A rarely diagnosed neutrophilic dermatosis of the elderly.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Erosive pustular dermatosis of the scalp (EPDS) is a rare, chronic inflammatory disorder characterized by sterile pustules, erosions, crusting, and scarring alopecia, which has been occasionally reported in association with epidermal growth factor receptor inhibitors (EGFRIs). Methods: We report two cases of EPDS induced by erlotinib therapy for non-small cell lung cancer (NSCLC). Case 1 involved a 73-year-old female with four years of erlotinib use presenting with scalp pustules, alopecia, and scarring. Case 2 was a 37-year-old male who developed papulopustular lesions on the scalp and trunk after six months of erlotinib therapy. Histopathological examination was performed on biopsy samples from both EPDS patients and compared with samples from two healthy controls. Results: Comparative analysis revealed neutrophilic infiltration, irregular epidermal hyperplasia, and elevated EGFR expression in hair follicles and epidermal keratinocytes in EPDS patients versus controls. These findings demonstrate how EGFR inhibition disrupts keratinocyte function and triggers inflammatory responses leading to severe follicular damage. Conclusion: These cases highlight the importance of dermatological monitoring in patients undergoing EGFRI therapy. Early recognition and management with antibiotics and topical steroids may help mitigate adverse effects. Further research is needed to elucidate underlying mechanisms and optimize treatment strategies for EPDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.